SEK 1.71
+0.13 (+8.43%)
SEK · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ONCO.ST is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 1 expanded access · 7 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple MyelomaNCT04918511Incidence and grade of Treatment Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: Sponsor made the decision to terminate the COAST study to refocus the OPD5 clinical program. | Drug: OPD5 | Relapse Multiple Myeloma, Multiple Myeloma | 0 | Mar 2024 | 2021-11-26 |
| Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple MyelomaNCT04649060results2023-06-08Progression Free Survival (PFS)Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The sponsor decided to terminate the study due to financial issues following an FDA request for a partial clinical hold. | Drug: Melflufen, Dexamethasone, Daratumumab | Relapsed Multiple Myeloma, Relapsed-Refractory Multiple Myeloma | 54 | 2022-02-07actual | 2023-06-08 |
| Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMMNCT03481556results2022-12-19Phase 1: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: The sponsor decided to terminate the study following an FDA request of a partial clinical hold. | Drug: Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib, Daratumumab | Multiple Myeloma | 56 | 2022-02-02actual | 2022-12-19 |
| A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) AmyloidosisNCT04115956The primary objective in Phase 1 is to explore safety and tolerability of melflufenOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The sponsor decided to terminate the study following an FDA request of a partial clinical hold. | Drug: Melphalan-Flufenamide (Melflufen), Dexamethasone | AL Amyloidosis | 6 | 2022-01-05actual | 2022-03-28 |
| PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal FunctionNCT03639610results2023-03-09Cmax of MelphalanNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The sponsor decided to terminate the study following an FDA request of a partial clinical hold. | Drug: Melflufen, Dexamethasone | Renal Impairment, Multiple Myeloma | 35 | 2021-12-22actual | 2023-03-10 |
| A PK, Safety and Tolerability Study of Peripheral and Central Infusion of Melflufen in RRMM PatientsNCT04412707results2022-08-16Peak Plasma Concentration for MelphalanRandomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: The sponsor decided to terminate the study following an FDA request of a partial clinical hold. | Drug: Melphalan, Dexamethasone | RRMM | 27 | 2021-06-02actual | 2023-03-09 |
| A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to LenalidomideNCT03151811results2022-07-27Progression Free Survival (PFS)Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Sponsor assessed all endpoints and collected Overall Survival data for another two years following the primary completion date of 03Feb2021. | Drug: Melflufen, Pomalidomide, Dexamethasone | Multiple Myeloma | 495 | 2021-02-03actual | 2024-01-30 |
| A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaNCT02963493results2022-02-01Overall Response Rate (ORR)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Melphalan flufenamide (Melflufen), Dexamethasone | Multiple Myeloma | 157 | 2020-10-22actual | 2022-11-22 |
| Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma PatientsNCT01897714results2020-08-24Percentage of Patients Who Achieved Best Overall Disease ResponseNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Terminatedsponsor's stated reason: The study was terminated at median 46-48 months long term follow-up and mature overall survival follow-up data. | Drug: Melflufen, Dexamethasone | Relapsed and/or Relapsed-refractory Multiple Myeloma | 75 | Dec 2017actual | 2020-10-23 |
| Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple MyelomaNCT04534322expanded access | — | Approved for marketing | Drug: Melphalan Flufenamide, Dexamethasone | Relapsed and/or Refractory Multiple Myeloma | — | — | 2021-03-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19